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for their efficacy in treating more complicated arrhythmias such as atrial fibrillation (AF) and ventricular
tachycardia (VT). This study will analyze cardiac ablation techniques and compare its treatment efficacy
to traditional or pharmaceutical forms of treatment for these specific arrhythmias.
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Abstract
Excitable groups of cells within the human heart can cause premature or abnormal
heart beats which can further develop into dangerous, arrhythmias. Cardiac Ablation is a
newer therapeutic method developed to treat these various types of arrhythmias. The
American Heart Association defines cardiac ablation as, "a therapeutic method used to
destroy a small section of heart tissue causing abnormal electrical activity or irregular
heartbeat." Ablative therapy has become the preferred method of treatment for several
arrhythmias such as AV nodal reentrant tachycardia (AVNRT), atrioventricular reentrant
tachycardia (AVRT), focal atria tachycardia, and atrial flutter (AFL). Ablative techniques
are also being used and tested for their efficacy in treating more complicated arrhythmias
such as atrial fibrillation (AF) and ventricular tachycardia (VT). This study will analyze
cardiac ablation techniques and compare its treatment efficacy to traditional or
pharmaceutical forms of treatment for these specific arrhythmias.
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Introduction
The primary role of the human heart is to pump blood and nutrients throughout
the entirety of the body. This is made possible by excitable groups of cells within the
heart that control the contraction rate of the four heart chambers: right atrium, left atrium,
right ventricle, and left ventricle. These excitable cells make up the conduction system of
the heart; they function by transmitting electrical impulses beginning at the sinoatrial
node (SA node) throughout the atria to the atrioventricular node (AV node). The AV
node holds the impulse for a fraction of a second allowing time for the atria to contract
and force blood into ventricles. From there, the impulse travels down the His-Purkinje
system and spreads throughout the ventricles inducing a heart contraction also known as
a heartbeat. Normal Sinus Rhythm describes the normal heart rate and rhythm of the
heart in which the electrical impulse follows the exact path described above resulting in a
heart rate between sixty and one hundred beats per minute (60-99 bpm). Any change or
variation in the normal sequence/timing of the electrical conduction system is described
as an arrhythmia, (American Heart Association [AHA], 2015).
There are many different types of arrhythmias, or abnormal heart beats, with
varying levels of severity and persistence. Some can be short-lived (i.e. a premature beat)
and have a very small effect on the heart's overall rhythm whereas others may be longlasting/permanent and result in significant reductions in the volume of blood pumped by
the ventricles per minute known as cardiac output (Q). This can be dangerous because
when Q is decreased, organs in the body may not receive a sufficient supply of blood
which can lead to them to be damaged or shut down entirely. Some common types of
arrhythmias include bradycardia (slow heart rate), tachycardia (fast heart rate),
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conduction disorders (within the AV junction and bundle branches), premature
contractions, and atrial/ventricle dysrhythmias. The type of arrhythmia can often be
diagnosed by analyzing abnormalities that take place during an electrocardiogram (ECG).
An ECG assesses the clectrical conduction system of the heart, (AHA, 2015).
Treatment methods for arrhythmias are also highly variable ranging from drug
therapy to invasive surgery depending on the type and severity of the arrhythmia. A
relatively newer form of treatment for some arrhythmias is cardiac ablation. The AHA
defines cardiac ablation as, "a therapeutic method used to destroy a small section of heart
tissue causing abnormal electrical activity or irregular heartbeat," (AHA, n.d.). The
ablation technique is a two-step process; first, the site of abnormal activity must be
identified using electrode catheters inserted through blood vessels and positioned inside
the heart. This step is referred to as cardiac mapping. Second, the abnormal tissue is
destroyed via radiofrequency ablation, a form of heat energy, or cyroablation, extremely
cold temperatures, delivered through a catheter to the site of abnormal tissue, (Tedrow,
Asirvatham, & Stevenson, 20 II). This study will analyze cardiac ablation treatment
techniques and compare its treatment efficacy to traditional or pharmaceutical forms of
treatment.

Literature Review
The first cardiac ablation was performed on humans in 1981 using a high energy
direct current (DC) shock to destroy the abnormal tissue. The DC shock created a high
voltage form of energy that lacked both precision and control. Radiofrequency (RF)
cardiac ablation was developed shortly after. RF cardiac ablation uses a low-voltage form
of energy thus enhancing the safety and applicability of the cardiac ablation technique.
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Cyroablation was the most recently developed; it destroys the abnormal tissue by
delivering temperatures from -60"Cto -80"Cto the target area. Other methods that utilize
acoustj.~ and laser technology to destroy the abnormal tissue are currently under
consideration and testing. Both RF cardiac ablation and cyroablation are commonly used
today, (Hassett, Swartz, & Bednarek, 2001; Tedrow et aI., 2011).
For the ablative therapy to be successful, the arrhythmia must be correctly
diagnosed and precisely mapped. When possible, arrhythmias can be correctly diagnosed
through ECG monitoring; however, ECG monitoring cannot always capture short-term,
non-persistent arrhythmias. In this case, diagnostic electrophysiological studies (EPS) are
necessary to ensure accurate diagnosis. During diagnostic EPS, the heart is electrically
stimulated to induce the abnormal, symptomatic arrhythmia so that it can be captured and
diagnosed. Furthermore, diagnostic EPS can provide conduction information detailing
SA nodal, AV nodal, and His-Purkinje functioning. Once diagnosed, the origin of the
arrhythmia must be mapped to ensure proper catheter positioning during the ablative
procedure, (Tedrow et aI., 2011).
For cardiac mapping of an arrhythmia, both fluoroscopy, an internal body
imaging technique, and other complex mapping systems are utilized to aid in proper
catheter placement. Mapping systems provide real-time three-dimensional images of the
cardiac anatomy, in addition to catheter positioning and electrophysiological information
about the tissue. In some cases, MRI, CT, and echocardiographic data are also required to
assist catheter placement and mapping, (Tedrow et aI., 2011). After the catheters have
been properly placed, the erratic cells can be destroyed.
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According to Bashore, Granger, Jackson, & Patel (20 I6), cardiac ablation has
proven both safe and effective with a rate of procedural complications ranging from one
to five percent. The most common risks associated with the procedure are related to the
catheterization process leading to damage of the vascular system with OCCUITencesat a
rate of two percent. Although there is a very low-risk, other possible complications
include pericardial tamponade, cardiac perforation, AV nodal damage, heart valve
damage, coronary artery damage, and systemic embolization, (Bashore et aI., 20 I6;
Tedrow, et a!., 201 I).
Cardiac ablation has already become the primary form of treatment for several
different arrhythmias, most commonly, various types of supraventricular tachycardias
such as AV nodal reentrant tachycardia (AVNRT), atrioventricular reentrant tachycardia
(AVRT), focal atria tachycardia, and atrial flutter (AFL). Ablative techniques are also
being used and tested for their efficacy in treating more complicated arrhythmias such as
atrial fibrillation (AF) and ventricular tachycardia (VT), (Bashore et a!., 2016).
In general, supraventricular tachycardia (SVT) describes several different
abnormal heart rhythms in which premature atrial depolarizations arise from an ectopic
stimulus somewhere in the atria or atrioventricular nodal tissue. Types of SVT arising in
the atria include sinus tachycardia, inappropriate sinus tachycardia, sinus nodal reentrant
tachycardia, focal atrial tachycardia, multi focal atrial tachycardia, AFL, and AF. Types of
SVT arising in the atrioventricular nodal tissue include AVNRT, AVRT, junctional
ectopic tachycardia, and non-paroxysmal junctional tachycardia. Most forms of SVT are
triggered by an electrophysiological mechanism known as reentry. In reentry, a
propagating impulse continually re-stimulates the heart creating a reentrant circuit. The
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exact reentrant path, severity, symptom manifestation, and treatment strategy are widely
variable depending on the specific type of arrhythmia, (Gugneja & Kraft, 2015).
The most common type of paroxysmal (sudden onset) SVT is AVNRT with a
prevalence of fifty to sixty percent in patients presenting with narrow QRS complexes,
(Gugneja & Kraft, 2015). AVNRT is so-named because the reentrant circuit takes place
within the AV nodal tissue. As a result, heart rate increases and typically ranges from
140-250 beats per minute (bpm). Despite the increase in speed, the heart rate remains
regular and constant. Although typical symptoms associated with AVNRT include
angina, shortness of breath, palpitations, and lightheadedness, other cases may present as
asymptomatic. Incidences may be short-term, lasting only a few brief seconds or longternl, lasting several hours/days. AVNRT can be identified on an ECG (Figure I) by the
lack of identifiable p-waves which become lost in the preceding beat; QRS complexes
will appear at a constant, rapid rate and may present as more narrow than normal. Still,
diagnostic EPS are generally essential for an accurate diagnosis, (Bashore et aI., 2016).

Figure 1. AV Nodal Reentrant Tachycardia (http://www.cardiacedu.com/ecg/avnrt.jpg).
The figure above is an example ECG for AVNRT demonstrating a regular, tachycardic
rhythm with unidentifiable p-waves.
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The mechanism of AVNRT onset (Figure 2) is made possible due to structure of
the AV nodal conduction system. In most people, the AV node consists of two pathways
connecting the atria to the ventricles, a slow pathway and a fast pathway, (Tedrow et aI.,

201 I). AVNRT is triggered by a premature atrial contraction. When the premature
stimulus reaches the AV node, the slow pathway may be ready to conduct but the fast
pathway may still be in recovery period from the previous contraction and unable to
conduct. If this occurs, the slow pathway will conduct the stimulus like nom1al in an
anterograde fashion during which time the fast pathway is still recovering. By the time
the conduction makes it through the slow pathway to the ventricles, the fast pathway may
be fully recovered and carryon the conduction in an anterograde fashion, from ventric.les
to atria. By the time the conduction makes it through the fast pathway to the atria, the
slow pathway may be fully recovered and the conduction can reenter the slow pathway
creating the tachycardic reentrant circuit, (Gugneja & Kraft, 20 15).

10
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Figure 2. AVNRT Reentry Mechanism. The image on the left represents the premature
contractile trigger, with only the slow pathway ready to pass on the anterograde
conduction. The middle image represents retrograde conduction through the fast pathway.
The image on the right represents the full tachycardic reentrant circuit.

Treatment of AVNRT requires interruption of the AV nodal reentrant circuit.
Current available treatments that aim to end the AVNRT episode include mechanical
maneuvers, drug therapy, and cardioversion. Because of their low risk, mechanical
maneuvers are usually the first treatment method attempted. Mechanical maneuvers aim
to increase vagal tone thereby ending the tachycardic episode. Both the Valsalva
maneuver and carotid sinus massage are commonly used, (Bashore et aI., 2016).
The Valsalva maneuver is an action in which the patient attempts forced
expiration with a closed glottis; as a result, intrathoracic pressure rises. At the onset of
straining, blood pressure increases due to the added intrathoracic pressure; however,
continued straining results in compression of the veins, decreased blood pressure,
decreased cardiac output, and inhibition ofbaroreceptors.

Then, once the glottis is

reopened, both intrathoracic pressure and cardiac output return to normal levels, but the
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blood vessels remain constricted due to the previously inhibited baroreceptors. The
constricted vessels cause an increase in blood pressure which in turn stimulates the
baroreceptors to lower the heart rate and blood pressure ending the tachycardic rhythm,
(Barrett, Barman, Boitano, & Brooks, 2016). Carotid massage is usually performed by a
physician while the patient's blood pressure and EKG are being closely monitored. The
technique involves rubbing of the one of the carotid arteries, located on both sides of the
neck, for 5 to 10 seconds where it divides into two main branches, the internal and
external carotid artery. Like the Val salva maneuver, this increases blood pressure which
then stimulates the arterial baroreceptors to lower heart rate and blood pressure ending
the tachycardic rhythm, (carotid sinus massage, n.d.).
If mechanical attempts are unsuccessful, drug therapy is the next mode of
treatment. The class of drug chosen for treatment is highly dependable on patient history
and symptom information; however, adenosine, calcium channel blockers, and beta
blockers are all commonly prescribed. Verapamil and diltiazem are calcium channel
blockers utilized to block conduction through the AV node thus ending the AVNRT
episode. Adenosine also functions to block conduction through the AV node. In contrast,
beta blockers antagonize the effects of sympathetic nerve stimulation and prolong AV
conduction thereby decreasing heart rate and ending the AVNRT episode. Although drug
therapy can be highly effective, it can also be unpredictable and have proarrhythmic
effects. In cases where drug therapy is unwarranted, cardioversion is a highly successful
and viable treatment option. Although all three of these strategies may be successful in
ending (he AVNRT episode, only drug therapy and ablation are permanent, preventative
measures, (Bashore et aI., 2016).
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Due to the side-effects of anti-arrhythmic drugs and high risk associated with
long-term drug therapy, cardiac ablation has been established as the preferential method
of treatment. Furthermore, the anatomy and dual conductive capacity of the AV node
make the ablative technique highly successful, (Gugneja & Kraft, 2015). The AV node is
made up of a dense center that connects the atria to the bundle of HIS and two or three
other lobes that project outward to spread the conduction. One of the lobes, extending
from the os of the coronary sinus to part of the tricuspid valve, forms the slow conduction
pathway. As described above, the slow conduction pathway is the location of reentry
triggering AVNRT. It is positioned so that it can be ablated without damaging all
transmission through the AV node leaving normal heart functioning in-tact once the
erratic tissue is destroyed, (Tedrow et a!., 20 I I).
The largest risk associated with the procedure is complete blockage of the AV
conduction system leaving the heart unable to function on its own and requiring
pacemaker implantation. Hindricks (1996) assessed this risk level and concluded there
was a 5 percent risk of complete AV block during a RF ablative procedure for AVNRT.
Another study, (Hanninen et a!., 2013) found cyroablation to be an extremely successful
method of AVNRT treatment. Their results indicated 0% of the patients treated with
cyroab:ation to have permanent AV block compared to the 0.8% treated with RF ablation
(n=I066) making it especially beneficially in the case of children and young adults where
risk of complete AV block is particularly large. However, additional results concluded
there is a larger prevalence of reoccurrence with cyroablation when compared to RF
r

ablation (P = 0.0002). Comparing the efficacy of drug therapy to ablative therapy,
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ablation is the preferred method of treatment for AVNRT with a success rate greater than
95 percent, (Tedrow et aI., 201 1; Gugneja & Kraft, 2015).
AVRT, the second most common paroxysmal SVT, has an incidence rate of 0.1 0.3 percent and male-to-female ratio of2:1, (Gugneja & Kraft, 2015). Like AVNRT,
AVRT is made possible due to the nature of the duel conduction system; however, unlike
AVNRT, only one conducting pathway follows the typical route through the AV node.
The other pathway bypasses the AV node forming a secondary, accessory pathway from
the atria to the ventricles indicative of Wolff-Parkins on-White Syndrome. By bypassing
the AV node, anterograde conduction through the accessory pathway doesn't "pause"
while the ventricles fill with blood. Therefore, the portion of the ventricles stimulated by
the accessory pathway contracts before the rest ofthe ventricles. The presence of
accessory pathways as seen in Wolff-Parkinson-White Syndrome is detectable on an
ECG by the presence of a short PR interval and delta waves (Figure 3). The delta waves
are indicative of the premature partial ventricular stimulation. If the accessory pathway
conducts in a retrograde fashion, it cannot be detected on an ECG during normal sinus
rhythm; these pathways are called concealed accessory pathways, (Gugneja & Kraft,
2015; Tedrow et aI., 2011).
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Figure 3. Wolff-Parkinson-White-Syndrome (2014). The ECG above exhibits a shortened
PR interval with the presence of delta waves as a result of the premature ventricular
contraction triggered by the accessory pathway.

Similar to the mechanism of AVNRT, a premature atrial contraction can create a
reentra'lt circuit through the accessory pathway triggering an episode of AVRT. In _
orthodromic AVRT, the reentrant circuit consists of anterograde conduction through the
AV node and retrograde conduction through the accessory pathway. In this case, ECG
readings demonstrate narrow QRS complexes often without any detectable p waves or
inverted p waves (Figure 4). Less common is antidromic AVRT in which the reentrant
circuit consists of retrograde conduction through the AV node and anterograde
conduction through the accessory pathway producing wide, bizarre QRS complexes on an
ECG (Figure 5). (Gugneja & Kraft, 2015).
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Figure 4.
Orthodromic AVRT (http://en.my-ekg.com/arrhythmias/supraventriculartachycardias.html). The above ECG represents a tachycardic arrhythmia with inverted p
waves (arrows) and narrow QRS complexes indicative of orthodromic AVRT.

Figure 5. Antidromic AVRT (2011). The above ECG represents a tachycardic arrhythmia
with no visible p waves and abnormal, misshapen QRS complexes indicative of antidromic
AVRT.

Common symptoms of AVRT include lightheadedness, syncope, and palpitations.
Because of the extremely fast rate the accessory pathway is able to conduct a stimulus,
patients with AVRT are at a high risk for entering atrial flutter or atrial fibrillation which
can further develop into ventricular fibrillation or sudden death, (Gugneja & Kraft, 2015).
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Risk factors for AVRT include male gender, age < 30, and history of AF or congenital
heart disease (CHD). Unless there is reason to believe there is poor conduction through
the accessory pathway, in which case drug therapy may be a plausible from of treatment,
patients with AVRT are at a high risk of unpredictable cardiac death and must undergo
ablative therapy. For cases in which drug therapy is warranted, the goal is to slow
conduction through the accessory path and AV node. To slow conduction through the
accessory path, common medications prescribed include class I agents, or sodium
channel blockers. Class Ia drugs, i.e. quinidine, slow the rate during the depolarization
phase of conduction whereas class Ic drugs, i.e. flecainide, slow the rate during the
repolarization phase of conduction. To slow conduction through the AV node,
prescription is similar to that of AVNRT including, class II agents, or beta blockers, and
class IV agents, or calcium channel blockers, (Bashore et aI., 2016).
Ablative therapy of AVRT targets the accessory pathway. Diagnostic EPS are
often required to both confirm the direction of conduction and determine the precise
location of the accessory pathway. Most commonly, accessory pathways are found
traversing through the tricuspid valve, mitral valve, or septum. The success rate of the
procedure is approximately 95 percent. A common complication of the procedure is
reappearance of conduction through the accessory pathway due to healing of the ablated
tissue occurring at a rate of 3 - 10 percent. Other possible rare complications include AV
block, cardiac tamponade, and hematoma formation, (Tedrow et aI., 2011). In most cases,
ablation is a superior treatment strategy compared to drug therapy and the preferred
methoc. of treatment for AVR T.
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Focal atrial tachycardia (AT) describes an abnormal arrhythmia beginning \\~thin
the atrial musculature creating a rapid heart rate between 150-250 bpm. Incidence rates
are approximately 2 percent in healthy, young adults and as high as 13 percent in the
elderly, (Prystowsky, Padanilam, & Waldo, 2011). Cases offocal AT may be
spontaneous, short episodes or persistent, chronic episodes. Three possible mechanisms
that trigger the tachycardic episode include abnormal automaticity, externally triggered
activity, or localized reentry. Pharmacological therapy is a possible treatment strategy,
but not always effective; it is generally only used for infrequent, short-term cases,
(Prystowsky et aI., 2011).
Ablation has become the standard form of treatment for focal AT with a success
rate greater than 80 percent, recurrence rate of 8 percent, and a complication rate of 1 to 2
percent. There is a wide range of possible origination locations including the tricuspid or
mitral region, coronary sinus musculature, atrial appendages, and pulmonary veins. As a
result, the appearance of focal AT on an ECG can be highly variable; therefore, the
tachycardia must be present or provocable for accurate mapping and catheter placement
to be possible (Tedrow et aI., 2011).
Atrial flutter (AFL) is an abnormal rhythm of the heart where the atria (upper
chambers) fire at rapid rate (240-340 beats per minute). The atria are essentially
"twitching", and many of the impulses don't reach the AV node resulting in an irregular
ventricular heart rate. Most commonly, conduction from the atria continues through the
AV node 50 percent of the time resulting in a ventricular rate around 150 bpm. AFL can
be identified on an ECG (Figure 6) by the presence of flutter waves which appear sawtoothed and jagged (Gugneja & Kraft, 2015).
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Figure 6. Atrial Flutter (2013). The ECG above contains flutter waves separated by
consis(.~nt, rapid QRS complexes characteristic of AFL.

Common symptoms of AFL include a tachycardia, angina, dyspnea, dizziness, .
lightheadedness, syncope, and heart palpitations (AHA, 2014). AFL generally presents
with other cardiac abnormalities such as hypertension, coronary artery disease, and sick
sinus syndrome. Both acute and permanent cases of AFL can result in decreased blood
pressure and myocardial ischemia; however, cardiomyopathy becomes a threat for more
persistent cases of AFL. In addition, AFL may present as a transitional arrhythmia
leading to atrial fibrillation or ventricular tachycardia, (Wellens, 2002).
There are two main types of AFL: Type I AFL and reverse typical flutter. Type I
AFL is the most common. Like most supraventricular tachycardia arrhythmias, AFL is
triggered by a reentry circuit. In type I AFL, the large reentrant circuit occurs in the right
atrium conducting in a counterclockwise direction whereas in reverse typical flutter, the
conduction follows the same path, but moves in a clockwise direction. Both types include
the right atrial isthmus, the bridge between the tricuspid valve and the region around the
inferior vena cava/coronary sinus, in the electrical circuit; this is a key component of the
reentrant circuit. Other less common types of AFL include left atrial flutter, double wave
reentry atrial flutter, lower loop reentry right AFL, and upper loop reentry right AFL,
(Prystowsky et a!., 20 I I).
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Treatment strategies for AFL include drug therapy, cardioversion, and ablation.
When an episode of AFL occurs, the first step is to terminate the tachycardic rhythm. For
temporary termination of AFL, class III drugs such as ibutilide, dofetilide, azimilide, and
sotalol are most frequently used. In addition, cardioversion has proven safe and
successful at terminating AFL in over 90% of incidents; however, it doesn't prevent
reoccurrences. To prevent further reoccurrences of AFL by inhibiting premature atrial
beats, Amiodarone and Class I drugs are the most efficacious. Due to the possible sideeffects associated with phannacological therapy, including pro-arrhythmic effects and
abnormal cardiac and kidney functioning, ablation is preferred method of long-term
treatment, (Wellens, 2002).
Both RF ablation and cyroablation have been proven safe and effective forms of
treatment for AFL. Currently, RF ablation is the most typical treatment for AFL; the
standard treatment uses endocardial activation mapping to localize the circuit. The
ablative technique attempts to' create a bi-directional block of the improper circuit thereby
terminating the arrhythmia, (Spitzer, Karolyi, Rammler, & Otto, 2002; Wellens, 2002).
When incorporated in the circuit, the right atrial isthmus is the most common ablated site
due to its 95 percent success rate making it significantly more effective than drug therapy
(Tedrow et aI., 2011). In a study by Manusama et al. (2004), the RF ablation technique
was compared to cyroablation technique for success in treating common AFL. Their
results also concluded cyroablation to be equally effective as RF ablation for both shortterm and long-term treatment of AFL; furthermore, cyroablation is perceived to be less
painful than the standard RF ablation technique. By demonstrating high success with low
complication rates, cardiac ablation has become the standard method of AFL treatment.
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Discussion
Ablative therapy has become the preferred method oftreatment for several
arrhythmias discussed above, but its uses are still being tested and developed for more
complicated arrhythmias. Atrial fibrillation (AF) is one such arrhythmia. AF describes an
arrhythmia in which, like AFL, the atria are essentially twitching at a rapid rate of 300 to
600 bpm. As a result, the ventricular rate is also rapid, 150-300 bpm, and irregular. The
appearance of the ECG reflects these abnormalities (Figure 7); the baseline appears wavy
and irregular representing the rapid atrial electrical activity with QRS complexes
intermittent and very erratic.

Figure 7. Atrial Fibrillation (2013). The above ECG exhibits a wavy, irregular baseline
with intermittent QRS complexes indicative of AF.

AF is the most common chronic arrhythmia effecting 2.2 million to 5 million
Americans with a prevalence of 0.4 percent in the general population and as high as 8.8
percent in the elderly (greater than 80 years old), (Prystowsky et aI., 20 II). Although AF
can develop in an otherwise healthy heart, "it is commonly associated with rheumatic
heart disease, hypertension, ischemic heart disease, pericarditis, thyrotoxicosis, alcohol
intoxication, disorders of the mitral valve, and digitalis toxicity," (Gugneja & Kraft,
2015). AF alone is rarely fatal; however, due to the atrial inactivity, patients with AF are
at a higher risk of embolism formation leading to a stroke then the general population. In
addition to AF, the presence of five other risk factors help predict risk of stroke:
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congestive heart disease, hypertension, age over 75, diabetes, and previous stroke history.
According to Bashore et al. (2016), patients with AF in addition to multiple other stroke
risk factors have a substantial 20 percent risk of stroke development compared to a 2
percent chance in patients with no other risk factors. Other possible consequences of AF
include hypotension, increased dementia risk, decreased cardiac output, hemodynamic
collapse, myocardial ischemia, and tachycardia-induced myocardial dysfunction,
(Bashore et aI., 2016; Michaud & Stevenson, 2015).
Despite some discrepancy, cases of AF are usually classified into one of three
broad categories: paroxysmal, persistent, or permanent. Paroxysmal AF describes cases
where AF episodes abruptly start and stop lasting for less than 7 days, though most cases
end within the first 24 hours. Paroxysmal AF is typically triggered by rapidly firing
ectopic cells or reentrant circuits located in the atrial musculature or pulmonary veins.
High alcohol consumption or alcohol withdrawal are also known to trigger paroxysmal
AF. In cases where AF lasts for longer than 7 days, it is categorized as persistent;
persistent AF generally requires electrical or pharmacological cardioversion. When AF
persists for over a year despite treatment attempts, it is categorized as permanent AF. The
longevity of both persistent and permanent AF is most often due to single or multiple
reentry circuits in addition to changes in the structure and anatomy of the atria to further
support reentry and sporadic, random contraction. Loss of myofibrils, the contractile
component of cardiac muscle, build-up of glycogen granules, and lack of cell-to-cell
communication/regulation

at gap junctions are all common atrial structural changes

opposing return to sinus rhythm. Other terms used to classify AF include first-detected
AF when only one episode has occurred, recurrent AF when two or more episodes have
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occurred, and lone AF when episodes occur in a patient with no other cardiac disorder.
Cases of AF may present as asymptomatic or symptomatic; palpitations, fatigue, anxiety,
dyspnea, angina, and dizziness are all common symptoms, (Prystowsky et aI., 2011;
Michaud & Stevenson, 2015).
The initial strategy for AF treatment requires management of symptoms and
lowering the risk of stroke or further complications associated with the arrhythmia. The
next step is involves choosing a permanent rate or rhythm control strategy. Because of
the variability in symptom manifestation, the form of symptom management is
determined on a case to case basis. More often than not, strategies applied for controlling
cardiac rate or rhythm are also effective in temlinating AF symptoms. Anticoagulants are
generally required for managing stroke risk. Warfarin, a vitamin K antagonist, is the
typical drug of choice; it has been shown to decrease stoke risk by 60 to 80 percent in
comparison to a placebo, (Prystowsky et aI., 2011). Newer anticoagulation drugs with
similar success to warfarin include dabigatran, rivaroxaban, and apixaban. The newer
drugs are associated with less negative drug/food interactions, therefore tend to have a
higher patient compliance than seen in patients prescribed warfarin. Dcspite the
necessary, positive effects of anticoagulation therapy, long-tcrm usage increases risk of
hemorrhage and bleeding, (Prystowsky et aI., 20 11).
As stated above, either a rate or rhythm control strategy is required for long-term
AF management. Several studies have shown no difference in success or mortality rates
when comparing rate versus rhythm control strategies; therefore, the method of treatment
is determined on a case to case basis. The goal of rate control is to decrease the
ventricular rate to less than 100 bpm thus increasing cardiac output and alleviating
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symptoms. Rate control strategies exist in two stages, acute and chronic. In the acute
stage, either beta blockers or calcium channel blockers may be administered to decrease
automaticity and prolong AV conduction. Depending on treatment urgency, the
medications may be delivered orally or intravenously. In cases where beta blockers or
calciuI'\ channel blockers alone are not sufficient in rate control, digitoxin may also be
prescribed, (Prystowsky et aI., 20 11; Michaud & Stevenson, 20 IS).
When AF and associated symptoms persist regardless of drug therapy attempts,
chronic rate control is essential. AV-nodal ablation resulting in complete heart block
followed by permanent pacemaker implantation is the typical form of chronic rate
control. Several studies (Kay ct aI., 1998; BrignoJe et aI., 1997) found improved quality
of life and ventricular functioning with the ablative-pacemaker method; however, the
procedure is not without limitations. Because this method doesn't tenninate the rapid
firing of the atria, the procedure does not replace the need for anticoagulation therapy,
and embolism formation still poses a major threat. In addition, this procedure is less
appealing for younger patients due to the likelihood of life-long pacing depcndency
(Prystowsky et aI., 2011; Michaud & Stevenson, 2015; Tedrow et aI., 2011).
Rhythm control strategies, as the name suggests, aim to maintain sinus rhythm.
This can be achieved through antiarrhythmic drugs, pharmacological cardioversion,
direct current cardioversion, or cardiac ablation each method with its own risks and
benefits. The method of therapy is chosen on a case to case basis depending on the
symptoms, risks, and needs of the individual. Antiarrhythmic drug therapy can be
successful, but also yields a high-risk for many side-effects; more than 20 percent of
patient receiving long-term drug therapy develop toxicities, (Michaud & Stevenson,
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2015). Therefore, drug therapy is not recommended in all cases, and the specific
antiarrhythmic is chosen based on side effect risk for a particular patient profile.
Class Ie antiarrhythmic agents, such as sodium channel blockers, effect the
purkinje fiber action potential by slowing repolarization. They have been shown to
prevent AF episodes, but increase the risk of AFL development; therefore, they are
avoided in patients with CHD or heart failure where AFL presents too high of a risk. In
patients without other heart disease, they can be used in combination with beta-blockers
or calcium channel blockers, but patients must still be highly ECG monitored. Class III
agents, such as dronedarone, sotalol, dofetilide, block potassium channels thereby
prolonging repolarization and slowing conduction. They can be useful for patients with
other h.~artconditions; however, long QT syndrome, an over-elongation of the QT
interval poses a threat requiring periodic ECG monitoring, (Prystowsky et a!., 2011;
Michaud & Stevenson, 2015; Bashore et aI., 2016). The most successful antiarrhythmic
drug in rhythm control is amiodarone, a class 111agent. Two thirds of patients
administered amiodarone maintain sinus rhythm compared to only 30 to 50 percent of
patients who benefit from receiving the other antiarrhythmic agents, (Michaud &
Stevenson, 2015).
Two forms of cardioversion have been used for rhythm control in AF patients,
pharmacological and direct current. In both forms of treatment, the need for
anticoagulation therapy needs to be addressed before the procedure. During the 48 hours
after first-detected AF onset, risk of stroke is usually low and cardioversion is a plausible
treatment technique. Because of the lowered risk of embolism formation during the first
48 hours, anticoagulation therapy is not usually needed preceding cardioversion except in
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extreme high-risk cases. In contrast, cases where timing of AF onset is unknown or
exceeds 48 hours, the risk of thromboembolism is higher. For cardioversion to be
applicable, echocardiographic data must obtained to ensure no thrombus presence.
Anticoagulation therapy may be necessary before or following cardioversion for weeks or
longer depending on patient's stroke risk (Prystowsky et aI., 2011; Michaud &
Stevenson, 2015).
The final strategy for rhythm control is cardiac ablation. Ablative techniques aim
to destroy the foci causing the rapid, erratic contractions; typical targets include both
electrical triggers such as pulmonary vein foci and atrial muscular foci, and atrial
substrate triggers such as fibrosis, hypertrophy, mutations of ion or gap junctions, and
electromechanical remodeling, (Lubitz, Fischer, & Fuster, 2008). Since 1998 when
ablative therapy was first attempted in treating AF, the technique has advanced from
linear ablation, pulmonary vein isolation, and left atrial linear ablation to ganglionic
plexus ablation, ablation of complex fragmented atrial electrocardiograms (CFAEs) and
most recently, box isolation, (Kumagai, 20 II). As stakd above, the pulmonary veins
have been identified as a common location for abnormal automaticity triggering AF
making them a primary target for ablative therapy. Furthermore, the pulmonary veinleft atrium junction has been identified as a common location ofreentry providing a
system to maintain the arrhythmia. The autonomic tone of the ganglionated plexi that
innervate the pulmonary veins and left atrium serves as a source of AF genesis thus the
ganglionic plexi have also become a target for ablation, (Kumagai, 20 II). Box isolation
aims to terminate AF by isolating both the posterior left atrium and pulmonary veins; the
posterior left atrium has been found to contain electrical triggers, reentry circuits,
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ganglionated plexi, and other abnormal substrates. Not all cases of AI' require the same
ablative technique; ablation producing pulmonary vein isolation may be a suitable form
of treatment for paroxysmal AI' whereas permanent AI' may require extensive ablation as
seen in ablation of CFAEs, (Kumagai, 2011).
Ablation has been most successful in treating paroxysmal AI' with success rates
as high as 70 to 80 percent in patients without other structural heart complications
(Tedrow et aI., 2011). The most common ablative techniques for treating paroxysmal AI'
include pulmonary vein isolation and box isolation (Kumagai, 2011).The effectfveness
of ablation therapy was compared to drug therapy in treating paroxysmal AI' in a five
trial meta-analysis study (Piccini et aI., 2009). They found 77 percent of the patients
treated with catheter ablation returned to sinus rhythm within one year of the procedure
with 17 percent requiring multiple ablative procedures and 2.6 percent enduring major
compli"ations. In comparison, only 29 percent of the patients that received drug therapy
returned to sinus rhythm after the one year period. Another meta-analysis study, (Calkins
et aI., 2009) found similar results. The ablative procedure was successful in 57 percent of
patients who received one treatment, 71 percent of patients who received multiple
treatments, and 77 percent in patients who received multiple treatments in combination
with drug therapy. The success rate of drug therapy alone was lower than all three
ablative therapy groups at 52 percent. Five percent of the ablation patients observed
major complications compared to 30 percent of the drug therapy patients; however, the
complications due to drug therapy were much less severe than the complications due to
ablative therapy.
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Cardiac ablation has been less successful in treating persistent and pernlanent
cases of AF, but new techniques and strategies are still being developed. To treat these
long-teml AF cases, more extensive ablation techniques are required. Typical techniques
include ablation via multiple linear lesions or ablation of CFAEs. CFAEs are defined as,
"fractionated electrocardiograms composed of 2 or more deflections with a mean cycle
length :5120 ms," (Kumagai, 20 II). They have been identified as a key location for vagal
innervation, slow conduction, reentry and AF maintenance. One study demonstrated
CFAE ablation to be successful in 93 percent of paroxysmal AF cases, 87 percent for
persist,.nt AF, and 78 percent for permanent AF; however, a similar study had much less
success with only 12 percent of patients receiving CFAE ablation returning to sinus
rhythm. Due to the difficulty in identifying the problem CFAE from the many other
bystanders, more study and testing needs to be done affirming the success of this ablative
technique (Kumagai, 20 II). Overall, many studies have demonstrated the superiority of
catheter ablation over drug therapy for termination of AF; however, data is still lacking
on the overall mortality and morbidity rates comparing the two different fOmlS of
treatment.
Cardiac ablation is also being developed for its use in treating ventricular
tachycardia (VT). VT is another rapid arrhythmia defined as three or more premature,
consecutive beats that arise in the ventricles. As a result, the ventricular rate typically
rises to 160 to 240 bpm whereas the atria are unable to contract at all. Premature
ventricular contractions (PVCs) are identifiable on an ECG appearing as widened,
defomled QRS complexes often lacking a preceding p wave (Figure 8). The typical
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mechanism for consecutive reoccurrence of PVCs leading to VT is reentry, (John &
Stevenson, 2015; Badhwar, 2014).

Figure 8. Premature Ventricular Contraction (2013). In the above ECG, normal sinus
rhythm is interrupted by the presence of PVCs appearing as widened, premature QRS
complexes.

There are two common ways to classify VT. The first is classification based on
duration; non-sustained VT describes a case in which the VT episode lasts less than thirty
seconds whereas sustained VT episodes last longer than thirty seconds. Sustained VT
requires intervention for termination. The second classification is based on the number of
ectopic sources triggering the arrhythmia. In monomorphic VT, each premature beats
arises from the same, single source. This is distinguished by a consistent QRS
morphology beat-to-beat (Figure 9). In contrast, polymorphic VT describes a case in
which several ventricular foci initiate premature beats distinguished by variation in QRS
morphology (Figure 10), (John & Stevenson, 2015; Badhwar, 2014).

Figure 9. Monomorphic VT (2013). The above ECG exhibits numerous wide, deformed
QRS complexes characteristic of VT. The consistent QRS morphology suggests the VT
episode is monomorphic.
.
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Figure 10. Polymorphic VT (http://www.medicine-on-line.com/html/ecg/eOOOlen_files
/08.htm). The above ECG exhibits numerous wide, deformed QRS complexes
characteristic of VT. The inconsistent QRS morphology suggests the VT episode is
polymorphic.

VT may present as asymptomatic or may result in several of the following
symptoms: palpitations, dizziness, exercise intolerance, episodes oflightheadedness,
syncope, or sudden death. In some cases, symptom evaluation can influence the treatment
strategy by providing information about the severity of VT and risk of sudden death,
(John &. Stevenson, 2015). Another important distinction for VT treatment describes
whether or not the arrhythmia occurs in conjunction with a structural heart disease or by
itself; VT is associated with a form of structural heart disease in 15 to 20 percent of cases,
(Badhwar, 2014). The most common disease associated with VT is chronic coronary
artery disease; however, cardiomyopathy, myocardial infarction history, and congenital
heart disease have led to VT episodes as well. Idiopathic VT, VT without the presence of
a structural heart disease, can present as monomorphic or polymorphic; it is often caused
by a discrete focal point or reentry circuits identifiable thorough electrophysiological
studies.
Idiopathic VT can be terminated with carotid massage, antiarrhythmic drugs, or
cardioversion, and treated with carotid massage, antiarrhythmic drugs, implanted cardio
defibrillators (ICDs), or ablation depending on the severity, duration, and symptom
manifestation. Typically, adenosine and beta blockers are prescribed for VT originating
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at a discrete focal point whereas verapamil, a calcium channel blocker, is prescribed for
reentrant idiopathic VT. Ablative therapy involves identifying the precise location of the
focal point or reentrant circuit. Idiopathic focal VT often originates near the right
ventricle outflow tract; in contrast, idiopathic reentrant VT often originates from reentry
in the fascicles of the left ventricle. In either case, ablation targets the area with the
earliest ventricular activation. Ablative therapy for treatment monomorphic, idiopathic
VT has a success rate greater than 80 percent (Tedrow et aI., 2011). However, ablation
for polymorphic, idiopathic VT has been much less successful and in most cases,
antiarrhythmic drugs are the preferred method of therapy.
The typical cause of VT in the presence of a structural heart disease is reentry
through areas of myocardial scarring. Treatment strategies include pharmacological
therapy, ICDs, and ablation. The mortality rate for VT with an associated heart disease is
much greater than idiopathic VT; as such, an ICD or ablative procedure is often
necessary. ICD is the standard treatment method for sustained VT in the presence of
structural heart disease. Although an ICD can be successful at ending the VT episode, the
defibrillator shocks have been associated with a higher risk of death and hospitalization.
Ablative therapy is often used in conjunction with an JCD to decrease the frequency of
shocking. Ablative therapy for monomorphic VT with associated structural diseases and
scarring has a success rate of approximately 70 percent with a 3 percent mortality rate.
Complications of the procedure include stroke, femoral hematomas, heart block which
can all lead to death. Furthermore, VT recurrence following ablation occurs in
approx:mately half of all patients, (Badhwar, 2014; Tedrow et aI., 2011).
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Although many of the studies discussed above didn't demonstrate or report
statistical significance, the results often demonstrated clinical significance. Statistical
significance only assesses the significance of the difference between the two groups
being evaluated, i.e. the group being treated versus the group receiving a placebo or two
groups receiving different treatments. Though this information can be highly valuable, it
doesn't indicate the meaningfulness of the outcome. This information is described by a
studies elinical significance which provides information about the effectiveness and
efficacy of the treatment strategy.

Conclusion
Cardiac ablation is a rapidly developing form of thcrapy that has already become
an effective treatment for many tachycardic arrhythmias. Ablative therapy has shown
superiority over pharmaceutical therapy in most cases of AV nodal reentrant tachycardia
(A VNRT), atrioventricular reentrant tachycardia (AVRT), focal atria tachycardia, and
atrial flutter (AFL). Despite its proven success, its necessity is usually assessed on a case
to case basis to ensure every patient receives the safest and most effective treatment
method.
Ablation has also become an option for atrial fibrillation (AF) and ventricular
tachyc"rdia (VT). Ablation has shown promise for the treatment of A-fib, although
research is still being done for long-term efficacy and effectiveness in certain
complicated cases. Ablation has become a common therapy for idiopathic monomorphic
VT treatment; however an ICD or pharmacological therapy is still more common for
polymorphic VT and VT occurring in the presence of identifiable heart disease. As m9re
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research is done in these areas, the overall cardiac ablation efficacy and practice will
continue to expand and save lives.

32

33

CARDIAC ABLATION: A THERAPEUTIC PERSPECTIVE
References

American Heart Association. (2014, October). Other Rhythm Disorders. Retrieved from
http://www.heart.org/HEARTORG/Conditions/

Arrhythmia! AboutArrhythmia!Oth

er-Rhythm-Disorders _UCM _302045_ Article.jsp#.VrJLU _krJn4
American Heart Association. (2015, October). About Arrhythmia. Retrieved from
http://www.heart.org/HEARTORG/Conditions/

Arrhythmia! AboutArrhythmia! Ab

out-Arrhythmia _UCM _0020 I0_Article.jsp#.VrIFnvkrJn4
American Heart Association. (n.d.). cardiac ablation. In Heart and Stroke Encyclopedia
online. Retrieved from http://www.heart.org/HEARTORG/Encyclopedia!HeartEncyclopedia _UCM _445084_ Encyclopedia.jsp?leveISelected=

13&title=cardiac

%20ablation
Antidromic AVRT [Online Image). (2011). Retrieved from
http://empharrnd.blogspot.com/2014/09/emergent-treatment-of-arrhythmias

.html

Atrial Fibrillation [Online Image). (2013). Retrieved from
http://www.ambulancetechnicianstudy.co.uk/rhythms.html#

.VsJFTPIrJn4

Atrial Flutter [Online Image). (2013). Retrieved from
http://www.ambulancetechnicianstudy.co.uk/rhythms.html#

.VsJFTPIrJn4

AV Nodal Reentrant Tachycardia [Online Image). Retrieved from
http://www.cardiacedu.com!ecg/ avnrt.j pg
Badhwar, N. (2014). Chapter 13. Ventricular Tachycardia. In Crawford M.H. (Eds),
Current Diagnosis & Treatment: Cardiology, 4e. Retrieved from
http://accessmedicine.mhmedical.com/
4545.

content.aspx?bookid= 715&Sectionid=4821

CARDIAC ABLATION: A THERAPEUTIC PERSPECTIVE

34

Barrett K.E., Barman S.M., Boitano S, Brooks H.L. (2016). Cardiovascular Regulatory
Mechanisms. In Barrett K.E., Barman S.M., Boitano S, Brooks H.L. (Eds),
Ganong's Review of Medical Physiology, 25e. Retrieved from
http://accessmedicine.mhmedical.com/

content.aspx ?bookid= 1587&Sectionid=97I

65959.
Bashore T.M., Granger C.B., Jackson K, & Patel M.R. (2016). Heart Disease. In
Papadakis M.A., McPhee SJ., Rabow M.W., Current Medical Diagnosis &
Treatment 2016. Retrieved from
http://accessmedici ne.mhmedical.com/ content.aspx?bookid= 1585&Secti onid=963
04476.
Brignole M, Gianfranchi L, Menozzi C, Alboni, P., Musso, G., Bongiomi, M., ...
Acquarone, S. (1997). Assessment of atrioventricular junction ablation and
DOOR mode-switching pacemaker versus pharmacological treatment in patients
with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled
study. Circulation. 96, 2617-2624. Retrieved from
http://circ.ahajoumals.org/content/96/8/2617.full
Calkins, H., Reynolds, M., Spector, P., Sondhi, M., Xu, Y., Martin, A., Williams, C., &
Sledge, 1. (2009). Treatment of atrial fibrillation with antiarrhythmic drugs or
radiofrequency ablation. Circulation: Arrhythmia and Electrophysiology, 2, 349361. doi: 10.1161/CIRCEP.108.824789.
Carotid sinus massage. (n.d.) Gale Encyclopedia of Medicine. (2008). Retrieved from
http://medicaldictionary.thefreedictionary

.coml carotid+sinus+massage

35

CARDIAC ABLATION: A THERAPEUTIC PERSPECTIVE
Gugneja, M., & Kraft, P. (2015). Paroxysmal Supraventricular Tachycardia. Medscape.
Retrieved from http://emedicine.medscape.comlarticle/156670-overvieW#a4
Hannil'en, M., Yeung-Lai-Wah, N., Massel, D., Gula, L.J., Skanes, A.C., Yee, R., ...
Leong-Sit, P. (2013). Cryoablation versus RF ablation for AVNRT: A meta-

analysis and systematic review. Journal of Cardiovascular Electrophysiology, 24
(12),1354-1360.

Retrieved from

http://www.ncbi.nlm.nih.gov/pubmedhealthlPMH0059448
Hassett, J., Swartz, J., Bednarek, M. (200 I). Process and device for the treatment of atrial
arrhythmia. Retrieved from https:llwww-googlecom.ezproxy.emich.eduipatents/US625

I I09

Healey, 1., Baranchuk, A., Crystal, E., Morillo,

c., Garfinkle,

M., Yusuf, S., Connolly, S.

(2005). Prevention of atrial fibrillation with angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers: a meta-analysis. Journal of
American College of Cardiology. 45,1832-1839. doi:10.1016/j.jacc.2004.11.070
Hindricks. (1996). Incidence of complete atrioventricular block following attempted
radiofrequency catheter modification of the atrioventricular node in 880 patients.
European Heart Journal. i7(1), 82-88. Retrieved from
http:// eurheartj .oxfordj oumals. org
John, R.M., & Stevenson, W.G. (2015). Ventricular Arrhythmias. In Kasper D, Fauci A,
Hauser, S., Longo, D., Jameson, J., Loscalzo, J. (Eds), Harrison's Principles of
internal Medicine, 1ge. Retrieved from
http://accessmedicine.mhmedical.coml
42328

content.aspx?bookid= 1130& Sectioni d=797

36

CARDIAC ABLATION: A THERAPEUTIC PERSPECTIVE
Kay, G.N., Ellenbogen, K.A., Giudici, M., Redfield, M., Jenkins, L., Mianulli, M.,
Wilkoff, B. (1998). The ablate and pace trial: a prospective study of catheter

ablation of the AV conduction system and permanent pacemaker implantation for
treatment of atrial fibrillation: APT Investigators. Journal Interview Cardiac
Electrophysiology, 2, 121-135. doi: 10.1023/ A: I009795330454
Kumagai, K. (2011). Catheter ablation of atrial fibrillation. Circulation, 75,2305 - 2311.
doi: 10.1253/circj.CJ-II-0658
Lubitz, S., Fischer, A., & Fuster, V. (2008). Catheter ablation for atrial fibrillation.
British Medical Journal. 336, 819-826.
http://dx.doi.orgIl0.1136/bmj.39513.555150.BE
Manusama, R., Timmermans, C., Limon, F., Philippens, S., Crijns, H., & Rodriguez, L.
(2004). Catheter-based cryoablation permanently cures patients with common
atrial flutter. Circulation, 109,1636-1639. Retrieved from
http://circ.ahajoumals.org/contentlI09l13/1636.
Michaud G.F., & Stevenson W.G. (2015). Supraventricular Tachyarrhythmias. In Kasper
D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J (Eds), Harrison's
Principles of Internal Medicine, 1ge. Retrieved from
http://accessmedicine.mhmedical.coml

content.aspx?bookid= 1130&Sectionid=797

42251.
Monomorphic VT [Online Image]. (2013). Retrieved from
http://www.ambulancetechnicianstudy.co.uklrhythms.html#
Orthodromic AVRT [Online Image]. Retrieved from http://en.myekg.coml arrhythmias/supraventricular-tachycardias.

html

.VsJFTPIrJn4

37

CARDIAC ABLATION: A THERAPEUTIC PERSPECTIVE
Piccini, J., Lopes, R., Kong, M., Hasselblad, V., Jackson, K., & AI-Khatib, S. (2009).
Pulmonary vein isolation for the maintenance of sinus rhythm in patients with
atrial fibrillation. Circulation: Arrhythmia and Electrophysiology, 2, 626-633.
doi: 10.1161/CIRCEP.I09.856633
Polymorphic VT [Online Image). Retrieved from http://www.medicine-online.com/html/ecg/eOOO len _files/08.htm
Premature Ventricular Contraction [Online Image). (2013). Retrieved from
http://www.ambulancetechnicianstudy.co.uk/rhythms.html#

.YsJFTPlrJn4

Prystowsky, E. N., Padanilam, B.1., & Waldo A.L. (2011). Chapter 40. Atrial Fibrillation,
Atrial Flutter, and Atrial Tachycardia. In Fuster Y, Walsh R.A., Harrington R.A.
(Eds), Hurst's The Heart, Be. Retrieved from
http://accessmedicine. mhmedical.com/ content.aspx?bookid=3 76&Secti onid=402 7
9769.
Spitzer, S., Karolyi, L., Rammler, C., & Otto, T. (2002). Primary closed cooled tip
:lblation of typical atrial flutter in comparison to conventional radiofrequency

•

ablation. Europace, 4, 265-271. Retrieved from http://www.idealibrary.com.
Tedrow U.B., Asirvatham S.1., & Stevenson W.G. (2011). Chapter 44. Electrophysiology
and Catheter-Ablative Techniques. In Fuster Y, Walsh R.A., Harrington R.A.
(Eds), Hurst's The Heart, 13e. Retrieved from
http://accessmedicine. mhmed ical.com/con tent.aspx?bookid= 376&Sectionid=402 7
9773.
Wellens, H. (2002). Contemporary management of atrial flutter. Circulation. 106,649652. Retrieved from http://circ.ahajoumals.org/content/I06/6/649.

CARDIAC ABLATION: A THERAPEUTIC PERSPECTIVE
Wolff-Parkinson-White-Syndrome

[Online Image]. (2014). Retrieved from

http:// ekg.academy /atrial-rhythms.aspx

38

